Investment
Features
FeesSafety
Academy
More
Pluang+

Janus Henderson AAA CLO ETF rated Sell due to risks from widening credit spreads and subpar performance.

Analyst Insights
03 Jun 2026
Seeking Alpha
View Source
Bearish
pluang ai news

The Janus Henderson AAA CLO ETF (JAAA) has been rated Sell because it offers insufficient compensation for the risks of poor performance expected over the next few years, mainly due to widening credit spreads. JAAA invests primarily in AAA-rated Arbitrage CLOs, which lack the monitoring benefits of Balance Sheet CLOs and may be less resilient in tough market conditions. Although the risk of capital loss is low, its risk/reward profile is less attractive compared to other zero-duration investment options for short-term capital allocation. Recent credit market trends highlight improved loan recoveries but declining bond recoveries, underscoring the importance of CLO structure and asset selection for investors.

More News

Lotto.com appoints new COO and VP of HR to drive US digital lottery expansion

Lotto.com appoints new COO and VP of HR to drive US digital lottery expansion

Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...

Company Fundamentals
Bullish
16 minutes ago
Worldline schedules H1 2026 results call for July 30, with webcast and Q&A for analysts.

Worldline schedules H1 2026 results call for July 30, with webcast and Q&A for analysts.

Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...

Company Fundamentals
Neutral
16 minutes ago
Ipsen repurchases 28,541 shares in early July at an average price of €166.05 per share.

Ipsen repurchases 28,541 shares in early July at an average price of €166.05 per share.

Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...

Company Fundamentals
Neutral
16 minutes ago
Ipsen Pharma repurchases 28,541 shares at an average price of €166 in early July 2026

Ipsen Pharma repurchases 28,541 shares at an average price of €166 in early July 2026

Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...

Company Fundamentals
Neutral
16 minutes ago
Barclays raises Hudbay Minerals price target to $32 on strong copper growth outlook.

Barclays raises Hudbay Minerals price target to $32 on strong copper growth outlook.

Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...

Analyst Insights
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App